CN102112146B - 免疫诱导剂 - Google Patents

免疫诱导剂 Download PDF

Info

Publication number
CN102112146B
CN102112146B CN200980130313.6A CN200980130313A CN102112146B CN 102112146 B CN102112146 B CN 102112146B CN 200980130313 A CN200980130313 A CN 200980130313A CN 102112146 B CN102112146 B CN 102112146B
Authority
CN
China
Prior art keywords
polypeptide
cells
seq
cancer
immunity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980130313.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102112146A (zh
Inventor
冈野文义
清水正树
斋藤孝则
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Priority to CN201410047289.2A priority Critical patent/CN103751771B/zh
Publication of CN102112146A publication Critical patent/CN102112146A/zh
Application granted granted Critical
Publication of CN102112146B publication Critical patent/CN102112146B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200980130313.6A 2008-08-05 2009-08-05 免疫诱导剂 Active CN102112146B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410047289.2A CN103751771B (zh) 2008-08-05 2009-08-05 免疫诱导剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP202065/2008 2008-08-05
JP2008202065 2008-08-05
PCT/JP2009/063881 WO2010016525A1 (ja) 2008-08-05 2009-08-05 免疫誘導剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410047289.2A Division CN103751771B (zh) 2008-08-05 2009-08-05 免疫诱导剂

Publications (2)

Publication Number Publication Date
CN102112146A CN102112146A (zh) 2011-06-29
CN102112146B true CN102112146B (zh) 2014-03-12

Family

ID=41663742

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980130313.6A Active CN102112146B (zh) 2008-08-05 2009-08-05 免疫诱导剂
CN201410047289.2A Active CN103751771B (zh) 2008-08-05 2009-08-05 免疫诱导剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410047289.2A Active CN103751771B (zh) 2008-08-05 2009-08-05 免疫诱导剂

Country Status (16)

Country Link
US (2) US8454968B2 (cg-RX-API-DMAC7.html)
EP (2) EP2324842B1 (cg-RX-API-DMAC7.html)
JP (2) JP5691171B2 (cg-RX-API-DMAC7.html)
KR (3) KR101669827B1 (cg-RX-API-DMAC7.html)
CN (2) CN102112146B (cg-RX-API-DMAC7.html)
AU (2) AU2009278385B2 (cg-RX-API-DMAC7.html)
BR (2) BR122020027042B1 (cg-RX-API-DMAC7.html)
CA (1) CA2732283C (cg-RX-API-DMAC7.html)
DK (2) DK2324842T3 (cg-RX-API-DMAC7.html)
ES (2) ES2619322T3 (cg-RX-API-DMAC7.html)
HU (1) HUE031343T2 (cg-RX-API-DMAC7.html)
MX (2) MX339277B (cg-RX-API-DMAC7.html)
PL (2) PL2324842T3 (cg-RX-API-DMAC7.html)
PT (2) PT2837383T (cg-RX-API-DMAC7.html)
RU (2) RU2511039C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010016525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2322221T3 (da) 2008-08-05 2014-09-01 Toray Industries Farmaceutisk sammensætning til behandling og forebyggelse af cancer
MX337991B (es) 2008-08-05 2016-03-30 Toray Industries Metodo para detectar cancer.
AU2011211699B2 (en) 2010-02-04 2015-01-22 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
JP5845899B2 (ja) 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び／又は予防用医薬組成物
HUE040012T2 (hu) * 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
BR112012018951C8 (pt) 2010-02-04 2020-06-23 Toray Industries anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
KR101842893B1 (ko) * 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
KR101871704B1 (ko) * 2010-02-04 2018-06-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CA2836568C (en) * 2011-05-19 2020-07-21 Toray Industries, Inc. Immunity induction agent
PT2740796T (pt) * 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
CN103764825B (zh) * 2011-08-04 2015-09-02 东丽株式会社 癌的治疗和/或预防用药物组合物
ES2672695T3 (es) * 2011-08-04 2018-06-15 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
MX348579B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
KR101968499B1 (ko) * 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
ES2629061T3 (es) 2011-08-04 2017-08-07 Toray Industries, Inc. Método para la detección de cáncer pancreático
ES2739380T3 (es) 2012-02-21 2020-01-30 Toray Industries Composición farmacéutica para el tratamiento del cáncer
AU2013223143B2 (en) 2012-02-21 2017-12-21 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX357505B (es) 2012-02-21 2018-07-12 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IN2014KN01714A (cg-RX-API-DMAC7.html) 2012-02-21 2015-10-23 Toray Industries
US9428581B2 (en) 2012-03-30 2016-08-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of gallbladder cancer
PT2832365T (pt) 2012-03-30 2018-01-24 Toray Industries Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático
CA2879185C (en) 2012-07-19 2021-08-24 Toray Industries, Inc. Method for detecting cancer
WO2014014082A1 (ja) 2012-07-19 2014-01-23 東レ株式会社 癌の検出方法
CA2918989C (en) 2013-08-09 2021-11-02 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX390696B (es) * 2015-04-30 2025-03-21 Toray Industries Agente inductor de inmunidad.
WO2018079740A1 (ja) * 2016-10-28 2018-05-03 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2019189780A1 (ja) * 2018-03-30 2019-10-03 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CN109206502B (zh) * 2018-09-26 2022-03-04 东北农业大学 一种猫干扰素ω及其制备方法和在抗病毒中的应用
CN109206501B (zh) * 2018-09-26 2022-03-04 东北农业大学 猫干扰素ω、其编码基因及其在抗病毒方面的应用
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
JP7852926B2 (ja) * 2020-06-26 2026-04-28 ファイム ファーマ リミテッド 乾癬及び他の自己免疫疾患抗原免疫モジュレータ（ａｉｍ）治療プラットフォーム

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678338A (zh) * 2002-08-30 2005-10-05 株式会社免疫新领域 调控调节性t细胞活性的方法及组合物
WO2005116051A2 (de) * 2004-05-25 2005-12-08 Immatics Biotechnologies Gmbh An mhc-moleküle bindende tumor-assoziierte peptide
WO2008088583A2 (en) * 2006-08-30 2008-07-24 Immunotope, Inc Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
TR200100916T2 (cg-RX-API-DMAC7.html) * 1998-07-14 2002-06-21 Corixa@@Corporation
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
JP4533626B2 (ja) * 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
CA2642342A1 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
KR20080075722A (ko) 2007-02-13 2008-08-19 엘지이노텍 주식회사 튜너
JP4826496B2 (ja) 2007-02-16 2011-11-30 三菱マテリアル株式会社 電解メッキ用アノード電極取付構造
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
US20140357512A1 (en) * 2013-06-03 2014-12-04 Acetylon Pharmaceuticals, Inc. Histone deacetylase (hdac) biomarkers in multiple myeloma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678338A (zh) * 2002-08-30 2005-10-05 株式会社免疫新领域 调控调节性t细胞活性的方法及组合物
WO2005116051A2 (de) * 2004-05-25 2005-12-08 Immatics Biotechnologies Gmbh An mhc-moleküle bindende tumor-assoziierte peptide
WO2008088583A2 (en) * 2006-08-30 2008-07-24 Immunotope, Inc Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEREX, Proteomex, AMIDA, and beyond:Serological screening technologies for target identification;Jens Rauch et al;《Proteomic Clinical Applications》;20080207;第2卷(第3期);355-371 *

Also Published As

Publication number Publication date
RU2639518C2 (ru) 2017-12-21
BRPI0912462A2 (cg-RX-API-DMAC7.html) 2016-02-02
MX348464B (es) 2017-06-14
KR101669827B1 (ko) 2016-10-27
KR20170128637A (ko) 2017-11-22
JP5691171B2 (ja) 2015-04-01
JP2015061847A (ja) 2015-04-02
DK2837383T3 (en) 2017-03-20
US9592281B2 (en) 2017-03-14
CA2732283C (en) 2017-12-05
US20130230488A1 (en) 2013-09-05
CN102112146A (zh) 2011-06-29
AU2009278385B2 (en) 2015-06-11
MX339277B (es) 2016-05-19
ES2539603T3 (es) 2015-07-02
WO2010016525A1 (ja) 2010-02-11
HUE031343T2 (hu) 2017-07-28
ES2619322T3 (es) 2017-06-26
EP2324842A4 (en) 2012-05-23
MX2011001113A (es) 2011-03-04
RU2011108315A (ru) 2012-09-10
PL2324842T3 (pl) 2015-08-31
US8454968B2 (en) 2013-06-04
CA2732283A1 (en) 2010-02-11
RU2511039C2 (ru) 2014-04-10
AU2009278385A1 (en) 2010-02-11
AU2015210461B2 (en) 2017-07-13
KR20160127146A (ko) 2016-11-02
BRPI0912462B1 (pt) 2022-03-22
AU2015210461A1 (en) 2015-09-03
JP5962739B2 (ja) 2016-08-03
KR20110044854A (ko) 2011-05-02
EP2324842A1 (en) 2011-05-25
PT2324842E (pt) 2015-07-21
EP2324842B1 (en) 2015-03-25
CN103751771A (zh) 2014-04-30
KR102009241B1 (ko) 2019-08-09
JPWO2010016525A1 (ja) 2012-01-26
US20110123492A1 (en) 2011-05-26
PT2837383T (pt) 2017-03-17
EP2837383A1 (en) 2015-02-18
RU2013156620A (ru) 2015-06-27
BR122020027042B1 (pt) 2022-11-08
CN103751771B (zh) 2017-09-08
DK2324842T3 (da) 2015-06-22
PL2837383T3 (pl) 2017-07-31
EP2837383B1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
CN103751771B (zh) 免疫诱导剂
CN104906597B (zh) 免疫诱导剂
US10463725B2 (en) Immunity inducing agent
AU2012256756B2 (en) Immunity induction agent
JP5217502B2 (ja) 癌の治療及び／又は予防剤
JP7160462B2 (ja) 免疫誘導剤
JP5572938B2 (ja) 免疫誘導剤
JPWO2017150595A1 (ja) 免疫誘導剤
JP2008247891A (ja) 癌の治療及び／又は予防剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant